Determination of uptake of fluorescent 3DNA in vitro and in vivo

This research project, conducted at the Philadelphia College of Osteopathic Medicine (PCOM) seeks to  understand the uptake of fluorescently labeled 3DNA, examining how this nucleic-acid-based platform is internalized and distributed both in vitro and in vivo. This work focuses on developing therapeutics to treat diseases of the eye, the study leverages the laboratory’s expertise in ocular cell biology and translational research and generating robust data on cellular uptake dynamics and tissue distribution that are essential for evaluating 3DNA as a delivery vehicle or diagnostic tool.

Such uptake studies inform downstream decisions about targeting, dosing, and formulation, and provide mechanistic insight into interactions between 3DNA constructs and the diverse cell types present in ocular tissues. Dr. George-Weinstein’s laboratory environment, which has produced over 50 peer-reviewed papers with substantial student co-authorship and includes co-inventorship on multiple patents, supports rigorous experimental design, data collection, and interpretation.

By focusing specifically on fluorescent 3DNA uptake, the study addresses a critical early-stage question for translational ocular research—whether and how a promising molecular construct can access target cells and tissues in controlled experimental settings and living systems. Results from the in vitro component will characterize uptake at the cellular level, while in vivo experiments will reveal distribution patterns within ocular structures and possibly related systemic compartments. These insights will inform future efforts to optimize 3DNA-based therapeutics or imaging agents for eye disease and will complement the lab’s ongoing mission to develop new interventions that protect retinal and neural function.